Nature NeuroscienceSystems BiologyPeer-reviewed journal article
Large-Scale Deep Multi-Layer Analysis of Alzheimer's Disease Brain Reveals Strong Proteomic Disease-Related Changes Not Observed at the RNA Level
Erik C. B. JohnsoniD, Kathleen CarteriD, Eric B. DammeriD, Duc M. DuongiD, Ekaterina Sergeevna GerasimoviD, Yue LiuiD, Jiaqi LiuiD, Ranjita S. BetarbetiD, Lingyan PingiD, Luming Yin, Geidy E. SerranoiD, Thomas G. BeachiD, Junmin PengiD, Philip L. De JageriD, Vahram H. HaroutunianiD, Bin ZhangiD, Chris GaiteriiD, David Alan BennettiD, Marla GearingiD, Thomas S. WingoiD, Aliza P. WingoiD, James J. LahiD, Allan I. LeveyiD, Nicholas T. SeyfriediD
Abstract
The biological processes that are disrupted in the Alzheimers disease (AD) brain remain incompletely understood. We recently performed a proteomic analysis of >2000 brains to better understand these changes, which highlighted alterations in astrocytes and microglia as likely key drivers of disease. Here, we extend this analysis by analyzing >1000 brain tissues using a tandem mass tag mass spectrometry (TMT-MS) pipeline, which allowed us to nearly triple the number of quantified proteins across cases. A consensus protein co-expression network analysis of this deeper dataset revealed new co-expression modules that were highly preserved across cohorts and brain regions, and strongly altered in AD. Nearly half of the protein co-expression modules, including modules significantly altered in AD, were not observed in RNA networks from the same cohorts and brain regions, highlighting the proteopathic nature of AD. Two such AD-associated modules unique to the proteomic network included a module related to MAPK signaling and metabolism, and a module related to the matrisome. Analysis of paired genomic and proteomic data within subjects showed that expression level of the matrisome module was influenced by the APOE {varepsilon}4 allele, but was not related to the rate of cognitive decline after adjustment for neuropathology. In contrast, the MAPK/metabolism module was strongly associated with the rate of cognitive decline. Disease-associated modules unique to the proteome are sources of promising therapeutic targets and biomarkers for AD.
- Citations
- 561
- FWCI
- 74.69
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Consensus Proteomic Analysis of Alzheimer's Disease Brain and Cerebrospinal Fluid Reveals Early Changes in Energy Metabolism Associated with Microglia and Astrocyte Activation
Erik C. B. Johnson, Eric B. Dammer, … Nicholas T. Seyfried·Nature MedicinePeer-reviewed·Apr 13, 2020
- Identification of conserved proteomic networks in neurodegenerative dementia
Vivek Swarup, Timothy S. Chang, … Daniel H. Geschwind·Cell ReportsPeer-reviewed·Jun 1, 2020
- Proteomic Signatures of Neuropathological Alterations in Alzheimer's Disease: Insights from the Bio-Hermes Study
Hanjun Zhao, Taiyu Zhu, … Laura M. Winchester·bioRxiv·May 22, 2026
- Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer's disease
Lingyan Ping, Sean R. Kundinger, … Nicholas T. Seyfried·Scientific DataPeer-reviewed·Sep 28, 2020
- Amyloid accumulation drives proteome-wide alterations in mouse models of Alzheimers disease like pathology
Jeffrey N. Savas, Yizhi Wang, … John R. Yates·Cell ReportsPeer-reviewed·Nov 1, 2017
- Compilation of all known protein changes in the human Alzheimer's disease brain
Manor Askenazi, Tomas Kavanagh, … Eleanor Drummond·bioRxiv·Apr 13, 2023